{"gene":"P2RY12","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2000,"finding":"SP1999 (P2RY12) is a Gαi-coupled receptor for ADP; ADP inhibits forskolin-stimulated adenylyl cyclase activity through selective activation of this receptor with an EC50 of 60 nM. The rank order of potency was 2-MeS-ATP = 2-MeS-ADP > ADP > other nucleotides. ATP showed no agonist activity but acted as a low-affinity antagonist.","method":"Heterologous expression in CHO cells, adenylyl cyclase inhibition assay, Ca2+ mobilization assay with chimeric Gαq/i, mass spectrometry identification of purified ligand from rat spinal cord extracts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in transfected cells with multiple orthogonal methods (functional assay, ligand purification and MS identification, pharmacological profiling), single rigorous paper","pmids":["11104774"],"is_preprint":false},{"year":2003,"finding":"Purified recombinant human P2Y12 receptor couples most robustly to Gαi2, and also effectively to Gαi1 and Gαi3, but shows little or no coupling to Gαo or Gαq. 2MeSADP is the most potent agonist (EC50 = 80 nM); ADP is ~1000-fold less potent. ATP acts as a low-affinity antagonist. RGS4 markedly enhances agonist-stimulated GTPase activity.","method":"Baculovirus expression in Sf9 cells, protein purification, reconstitution in lipid vesicles with purified Gα subunits and Gβ1γ2, steady-state GTPase assay","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified components, multiple G protein subunit combinations tested, rigorous functional assay","pmids":["14573771"],"is_preprint":false},{"year":2003,"finding":"The active metabolite of clopidogrel binds covalently and irreversibly to P2Y12 on platelets and in stably transfected CHO cells, blocking 33P-2MeS-ADP binding and ADP-induced adenylyl cyclase downregulation. P2Y12 corresponds to the previously designated 'P2T/P2TAC' receptor.","method":"Stable expression in CHO cells, radioligand binding assay (33P-2MeS-ADP), adenylyl cyclase inhibition assay, pharmacological profiling with clopidogrel active metabolite","journal":"Seminars in vascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and functional assay in transfected cells, consistent with earlier published work, single lab review summarizing original findings","pmids":["15199474"],"is_preprint":false},{"year":2005,"finding":"P2Y12 desensitization is mediated by G protein-coupled receptor kinases (GRK2 and GRK6), but not by protein kinase C. This is distinct from P2Y1, whose desensitization is largely dependent on PKC activity. Both GRKs are endogenously expressed in platelets.","method":"Transient overexpression of dominant-negative GRK mutants and siRNA knockdown in 1321N1 cells; platelet aggregation desensitization assays in human platelets","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — dominant-negative mutants and siRNA knockdown as orthogonal approaches in two cell systems, clearly distinguishes mechanism from P2Y1","pmids":["15665114"],"is_preprint":false},{"year":2004,"finding":"P2Y12 receptor activation in CHO cells triggers two distinct signaling pathways: (1) Gi-dependent activation of PI3-kinase/Akt upstream of MAP-kinases leading to cell proliferation, with partial contribution via transactivation of PDGF-Rβ; (2) Gi-independent RhoA/Rho-kinase activation leading to actin cytoskeleton reorganization. Both pathways are blocked by the active metabolite of clopidogrel.","method":"Stable expression in CHO cells, pharmacological inhibition (pertussis toxin, PI3K inhibitors, Rho-kinase inhibitors), cell proliferation assays, actin cytoskeleton imaging","journal":"Journal of thrombosis and haemostasis : JTH","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological dissection approaches in single cell system, two orthogonal readouts (proliferation vs. actin), single lab","pmids":["14717977"],"is_preprint":false},{"year":2008,"finding":"The Gi-coupled P2Y12 receptor regulates diacylglycerol (DAG)-mediated signaling in platelets: P2Y12 stimulation inhibits diacylglycerol kinase-mediated phosphorylation of DAG to phosphatidic acid, thereby sustaining DAG levels and enhancing PKC activation and Rap1b activation downstream of Gq-coupled receptors. This effect requires PI3-kinase rather than adenylyl cyclase inhibition.","method":"Platelet aggregation assays, pleckstrin phosphorylation (PKC readout), Rap1b activation assay, diacylglycerol kinase inhibition, pharmacological blockade of P2Y1 and P2Y12 receptors, phorbol ester bypass experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal pharmacological tools and functional readouts in human platelets, mechanistic dissection of DAG/PKC pathway, single rigorous paper","pmids":["18755689"],"is_preprint":false},{"year":2008,"finding":"P2Y12 mRNA and protein are upregulated in spinal cord microglia following partial sciatic nerve ligation, peaking at day 3. P2Y12 activation by ADP/hydrolyzed ATP acts as a gateway for p38 MAPK phosphorylation in spinal microglia; intrathecal P2Y12 antagonist or antisense knockdown suppressed p38 activation and neuropathic pain behaviors. Intrathecal P2Y12 agonist in naive rats mimicked nerve injury-induced p38 activation.","method":"Rat partial sciatic nerve ligation model, double-label in situ hybridization/immunohistochemistry, intrathecal pharmacological blockade, antisense knockdown, Western blot for p-p38","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — antisense knockdown and pharmacological blockade with consistent phenotypes, agonist mimicry experiment, mechanistic pathway placement (P2Y12→p38 MAPK), single rigorous study","pmids":["18337420"],"is_preprint":false},{"year":2012,"finding":"P2RY12 is the primary ADP receptor in osteoclasts (OCs). ADP stimulation of P2RY12 activates RAP1 and enhances OC adhesion and bone resorptive activity. P2ry12-/- OCs show intact differentiation but diminished resorptive function and blunted ADP-induced RAP1 activation. P2ry12-/- mice are partially protected from age-associated bone loss, arthritis-induced osteolysis, tumor-induced osteolysis, and ovariectomy-induced osteoporosis.","method":"P2ry12-/- mice, bone resorption assays, RAP1 activation assay, integrin β3 knockout comparison, in vivo bone loss models (FeCl3 arthritis, tumor, ovariectomy), clopidogrel pharmacological treatment","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple in vivo disease models, RAP1 signaling assay, pharmacological validation, multiple orthogonal approaches","pmids":["22996695"],"is_preprint":false},{"year":2012,"finding":"P2Y12 receptor internalization requires interaction of its PDZ-binding motif with NHERF1. Prior to agonist stimulation, NHERF1 binds directly to the receptor C-tail. Upon agonist stimulation, NHERF1 no longer binds the receptor directly but instead interacts via arrestin as a scaffold, promoting NHERF1-dependent receptor internalization.","method":"Co-immunoprecipitation, mammalian cell overexpression, receptor internalization assays, dominant-negative and mutant receptor constructs, in vitro binding assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and functional internalization assay with mutant constructs, mechanistic model of arrestin-NHERF1-receptor ternary complex, single lab","pmids":["22610101"],"is_preprint":false},{"year":2014,"finding":"Crystal structure of human P2Y12R at 2.6 Å resolution in complex with antagonist AZD1283 reveals: (1) a distinct straight conformation of helix V unique among class A GPCRs; (2) absence of the conserved disulfide bridge between helix III and ECL2 (appears dynamic); (3) a non-nucleotide ligand-binding site with an adjacent pocket suggesting both pockets are required for dinucleotide binding.","method":"X-ray crystallography at 2.6 Å resolution","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure, unique structural features experimentally defined, published in Nature","pmids":["24670650"],"is_preprint":false},{"year":2014,"finding":"Crystal structures of human P2Y12R bound to full agonist 2MeSADP (2.5 Å) and partial agonist 2MeSATP (3.1 Å) reveal large-scale conformational rearrangements in the extracellular region required for agonist access to the binding pocket — the first example of such rearrangement for a GPCR. Agonist and non-nucleotide antagonist (AZD1283) adopt different orientations with only partially overlapping binding pockets.","method":"X-ray crystallography at 2.5 Å and 3.1 Å resolution, docking studies, comparison with antagonist-bound structure","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — two high-resolution crystal structures with functional interpretation, mechanistically defines agonist vs antagonist binding landscapes","pmids":["24784220"],"is_preprint":false},{"year":2016,"finding":"P2RY12-mediated chemotaxis of microglial processes is required for rapid closure of the blood-brain barrier following laser-induced BBB breakdown. Both pharmacological inhibition (clopidogrel) and genetic ablation of P2RY12 significantly diminished juxtavascular microglial process movement and failed to close laser-induced BBB openings.","method":"Two-photon live imaging of microglial processes in mice, laser-induced BBB opening, P2RY12 genetic knockout mice, clopidogrel pharmacological inhibition, fluorescent tracer BBB permeability assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — live imaging with genetic and pharmacological convergence, specific functional readout (BBB closure), two orthogonal approaches","pmids":["26755608"],"is_preprint":false},{"year":2016,"finding":"ADP activation of P2Y12 receptor in VSMCs inhibits macroautophagy via the PI3K-AKT-MTOR pathway, blocking LC3 maturation, SQSTM1 degradation, and autophagosome formation, thereby reducing cholesterol efflux and promoting foam cell formation. P2Y12 receptor inhibition promotes VSMC autophagy and cholesterol efflux in an ATG5-dependent manner.","method":"ApoE-/- mouse atherosclerosis model, siRNA knockdown and pharmacological inhibition of P2Y12R, phosphoproteomic analysis, Western blot for LC3/SQSTM1, autophagosome TEM, cholesterol efflux assay, rapamycin rescue experiment, ATG5 knockdown epistasis","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (phosphoproteomics, genetic knockdown, pharmacological inhibition, epistasis with ATG5 and mTOR), in vivo and in vitro concordance","pmids":["32160082"],"is_preprint":false},{"year":2016,"finding":"Sustained ADP/P2RY12 signaling in vascular smooth muscle cells induces senescence via sustained Ras activation. Mechanical stretch increases ADP release from SMCs; P2ry12 genetic knockout in mice protects against SMC senescence, inflammation, and TAAD formation and rupture. Pharmacological Ras inhibition also protected against SMC senescence.","method":"P2ry12-/- mice, excessive mechanical stretch model, SA-β-gal staining, senescence marker Western blotting, HPLC and luciferin-luciferase ADP measurement, Ras activation assay, pharmacological Ras inhibition","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with multiple phenotypic readouts and Ras pathway placement, single lab","pmids":["27534720"],"is_preprint":false},{"year":2019,"finding":"ADP acting on microglial P2Y12 receptor activates NF-κB signaling and potentiates NLRP3 inflammasome activation, leading to enhanced IL-1β and IL-6 production. Mechanistically, ADP altered mitochondrial membrane potential in combination with ATP and increased caspase-1 positive cells through P2Y12 receptor.","method":"P2Y12 receptor-deficient microglia, siRNA knockdown, PSB0739 pharmacological blockade, NF-κB reporter assay, IL-1β/IL-6 ELISA, caspase-1 flow cytometry, mitochondrial membrane potential assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic deficiency and siRNA knockdown with pharmacological confirmation, mechanistic pathway placement (ADP→P2Y12→NF-κB/NLRP3→IL-1β), single lab","pmids":["31549730"],"is_preprint":false},{"year":2019,"finding":"Microglial P2Y12 receptor regulates ventral hippocampal CA1 neuronal excitability and innate fear behavior. Constitutive and induced conditional P2Y12R knockout mice exhibited increased innate fear and elevated CA1 neuronal excitability (assessed by c-fos expression and whole-cell patch clamp). Microglial process chemotaxis toward ADP/ATP gradients is mediated by P2Y12R.","method":"Conditional microglial P2Y12R knockout mice (CX3CR1-Cre and CX3CR1-CreER), behavioral testing (elevated plus maze), c-fos immunostaining, whole-cell patch clamp recording in ventral hippocampus CA1","journal":"Molecular brain","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent conditional knockout approaches (constitutive and inducible) with convergent behavioral and electrophysiological phenotypes, direct mechanistic link between microglial P2Y12R and neuronal excitability","pmids":["31426845"],"is_preprint":false},{"year":2021,"finding":"P2RY12 receptors on capillary-associated microglia (CAMs) regulate vascular structure and function under the control of purines released from pannexin-1 (PANX1) channels. P2RY12-/- and PANX1-/- mice phenocopied microglial depletion in causing capillary dilation, increased blood flow, and impaired vasodilation, establishing a PANX1-P2RY12 coupling mechanism for neurovascular regulation.","method":"P2RY12-/- and PANX1-/- mice, microglial depletion and repopulation, two-photon live imaging, blood flow measurement, ultrastructural analysis, spatio-temporal morphological characterization","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent knockout lines phenocopy each other and microglial depletion, multiple imaging modalities, functional vascular readouts","pmids":["34489419"],"is_preprint":false},{"year":2022,"finding":"P2Y12 receptor is expressed by macrophages in fibrosing kidneys (>82% of P2Y12-expressing cells are macrophage-origin); activation by TGF-β1 induces P2Y12 expression and promotes macrophage-to-myofibroblast transition (MMT) via the Smad3-dependent signaling pathway. Silencing or pharmacological inhibition of P2Y12 blocked TGF-β/Smad3-mediated MMT and progressive renal fibrosis.","method":"LysM-Cre/Rosa Tomato lineage tracing mice, UUO model, P2Y12 siRNA knockdown, clopidogrel treatment, single-cell RNA sequencing, α-SMA/CD68 co-immunostaining, in vitro TGF-β1 stimulation, Smad3 pathway analysis","journal":"Molecular therapy : the journal of the American Society of Gene Therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — lineage tracing for cell identity, genetic and pharmacological convergence, scRNA-seq pathway analysis, Smad3 mechanistic placement, in vivo and in vitro concordance","pmids":["35791881"],"is_preprint":false},{"year":2017,"finding":"P2Y12R homodimerization is critical for receptor function and signaling. A dominant negative variant R265P in extracellular loop 3 (EL3) disrupts the binding pocket conformation, reduces agonist-stimulated signaling and receptor surface loss, and acts in a dominant negative manner by impairing wild-type homodimer function. R265 is one of four residues required for receptor functional integrity.","method":"Next-generation sequencing/Sanger sequencing of patient family, mammalian cell overexpression of R265P mutant, receptor surface expression (flow cytometry/Western blot), Gi signaling assays, dominant negative co-expression experiments, platelet aggregometry, P2RY12 cDNA cloning from patients","journal":"Journal of thrombosis and haemostasis : JTH","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant negative co-expression with mechanistic interpretation of homodimerization, single lab, patient-derived validation","pmids":["29117459"],"is_preprint":false},{"year":2023,"finding":"Microglial P2Y12R mediates microglial process chemotaxis toward Tau oligomers and facilitates degradation of Tau deposits via Arp2-associated podosome and filopodia formation. P2Y12 receptors colocalize with F-actin-rich podosomes and filopodia during Tau-deposit degradation. Blockage of P2Y12 signaling decreased microglial migration and Tau-deposit degradation.","method":"N9 microglia cell culture, fluorescence microscopy for actin microstructures (podosome, filopodia, uropod), P2Y12 pharmacological blockade, colocalization with Arp2/TKS5/WASP scaffold proteins, Tau oligomer treatment","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — imaging-based colocalization with pharmacological blockade, functional migration and phagocytosis readouts, single lab","pmids":["37221563"],"is_preprint":false},{"year":2023,"finding":"Microglial P2Y12R mediates microglial participation in general anesthesia. Blocking P2Y12R pharmacologically or genetic ablation of P2Y12R specifically in microglia (CX3CR1-Cre) shortened duration of loss of righting reflex (unconsciousness) from multiple anesthetics and attenuated anesthesia-accompanying analgesia and hypothermia.","method":"Microglial depletion, microglial repopulation, chemogenetic activation, conditional P2Y12R knockout (CX3CR1-Cre), pharmacological P2Y12R blockade, single-cell RNA sequencing of anesthesia-affected transcriptional programs","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological convergence with multiple anesthetics, conditional knockout confirms microglial P2Y12R specificity, multiple behavioral readouts","pmids":["37167975"],"is_preprint":false},{"year":2022,"finding":"Platelet P2Y12-dependent CD40L release mediates anti-tumor activity of platelets in NAFLD-associated HCC. Pharmacological inhibition or genetic depletion of P2Y12 abrogated CD40L release from platelets, reduced CD8+ T cell activation via the CD40 receptor, and accelerated HCC growth.","method":"P2Y12 genetic depletion, pharmacological inhibition, in vivo transfusion of WT vs CD40L-/- platelets, HCC tumor models in NAFLD mice, liver metastasis models","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological convergence with CD40L-/- platelet rescue experiment establishing mechanism, single lab, multiple models","pmids":["36055226"],"is_preprint":false},{"year":2010,"finding":"P2ry12 functions in thrombin/PAR-independent pathways in vivo for hemostasis models, while in arterial thrombosis models PAR signaling was dominant. P2ry12 acts downstream of PARs to amplify platelet responses to thrombin ex vivo. P2ry12+/- platelets showed partially decreased ADP responses resembling clopidogrel-treated human platelets. Par3-/-:P2ry12-/- double-mutant mice showed combined additive protection against carotid thrombosis.","method":"P2ry12-/- and PAR knockout mice, platelet aggregation assays ex vivo, carotid artery thrombosis models with varying FeCl3 injury levels, intravital microscopy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis in double-knockout mice with multiple in vivo and ex vivo models, pathway placement of P2ry12 relative to PAR signaling, single lab","pmids":["20930120"],"is_preprint":false},{"year":2015,"finding":"P2Y12 expression is increased in alternatively activated (M2) human microglia compared to resting or classically activated (M1) microglia. M2 microglia show increased ADP-induced calcium responses that are blocked by selective P2Y12 antagonism. P2Y12 antagonism decreases migratory and inflammatory responses in human microglia upon nucleotide exposure; no effects were observed in human monocytes or macrophages.","method":"In vitro human microglia activation (M1/M2 conditions), flow cytometry, calcium imaging, P2Y12 antagonist pharmacological blockade, migration assays, in situ immunohistochemistry of MS and parasitic CNS infection brain samples","journal":"Neurology(R) neuroimmunology & neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional calcium and migration assays with pharmacological blockade, in vitro and in situ convergence, single lab","pmids":["25821842"],"is_preprint":false},{"year":2021,"finding":"NOD2 activation in sepsis upregulates platelet P2Y12 expression via the RIP2/NF-κB/P65 pathway, leading to constitutive P2Y12 activation (evidenced by enhanced pAkt and impaired pVASP in resting platelets) and platelet hyperactivity. NOD2 deficiency attenuated sepsis-induced platelet P2Y12 high expression, hyperactivity, and thrombosis.","method":"Septic patient platelets, CLP mouse model, NOD2-/- mice, Western blot (pAkt, pVASP as P2Y12 signaling readouts), platelet aggregation assays, NF-κB pathway analysis","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — NOD2-/- genetic validation, human patient and mouse model convergence, mechanistic pathway (NOD2→RIP2→NF-κB→P2Y12) placement, single lab","pmids":["34748820"],"is_preprint":false},{"year":2015,"finding":"P2Y12 receptor activation in trigeminal ganglion neurons mediates ADP-induced intracellular Ca2+ release from ryanodine-sensitive stores via a cAMP-dependent pathway. In the absence of extracellular Ca2+, ryanodine receptor inhibitors blocked 2-MeS-ADP-induced Ca2+ increases, and adenylate cyclase inhibition mimicked agonist effects.","method":"Rat TG neuron culture, immunofluorescence, calcium imaging with selective P2Y12 antagonists, ryanodine receptor blockers, SERCA inhibitor, adenylate/phosphodiesterase inhibitors, extracellular calcium chelation","journal":"Neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with multiple inhibitors in primary neurons, cAMP→ryanodine receptor pathway placement, single lab","pmids":["25987295"],"is_preprint":false}],"current_model":"P2RY12 is a Gαi2-coupled GPCR (also coupling to Gαi1/Gαi3 but not Gαo/Gαq) activated by ADP that inhibits adenylyl cyclase, activates PI3K/Akt and Rap1b, regulates diacylglycerol signaling via diacylglycerol kinase suppression, and triggers RhoA/Rho-kinase-dependent actin reorganization; its structure has been resolved in agonist- and antagonist-bound states revealing large-scale extracellular rearrangements for agonist access; it undergoes GRK2/GRK6-mediated desensitization and arrestin/NHERF1-dependent internalization; on platelets it amplifies activation, granule secretion, and thrombus formation; on microglia it mediates chemotaxis toward ATP/ADP gradients, blood-brain barrier closure, PANX1-coupled neurovascular regulation, p38 MAPK-driven neuropathic pain, NF-κB/NLRP3 inflammasome activation, and modulation of neuronal excitability and anesthesia sensitivity; in vascular smooth muscle cells it promotes senescence via sustained Ras activation and foam cell formation via PI3K-AKT-MTOR-dependent autophagy suppression; and in macrophages it drives TGF-β/Smad3-mediated myofibroblast transition and in platelets mediates CD40L release for anti-tumor CD8+ T cell responses."},"narrative":{"mechanistic_narrative":"P2RY12 is a Gαi-coupled G-protein-coupled receptor for ADP that suppresses adenylyl cyclase and, through this and parallel effectors, transduces purinergic signals in platelets, microglia, and vascular and immune cells [PMID:11104774, PMID:14573771]. Pharmacological and reconstitution studies establish it as the clopidogrel target, originally designated the platelet P2T/P2TAC receptor: the clopidogrel active metabolite binds covalently and irreversibly to abolish ADP-induced signaling, while ATP acts as a low-affinity antagonist and 2-MeS-ADP is the most potent agonist [PMID:14573771, PMID:15199474]. The receptor couples most robustly to Gαi2 (and to Gαi1/Gαi3 but not Gαo/Gαq), and beyond cyclase inhibition it drives two largely separable outputs — Gi-dependent PI3-kinase/Akt activation feeding MAP-kinase signaling and proliferation, and Gi-independent RhoA/Rho-kinase-dependent actin reorganization [PMID:14573771, PMID:14717977]. Downstream of these effectors P2RY12 sustains diacylglycerol levels by inhibiting diacylglycerol kinase to potentiate PKC and Rap1b activation, amplifying platelet responses to thrombin/PAR signaling [PMID:18755689, PMID:20930120], and activates Rap1 to enhance osteoclast adhesion and bone resorption [PMID:22996695]. Crystal structures in antagonist-bound (AZD1283) and full/partial agonist-bound (2MeSADP/2MeSATP) states reveal a class-A-atypical straight helix V, a dynamic helix III–ECL2 disulfide, and large-scale extracellular rearrangements required for agonist access, with agonist and non-nucleotide antagonist occupying only partially overlapping pockets [PMID:24670650, PMID:24784220]. Receptor signaling is terminated by GRK2/GRK6-mediated desensitization and arrestin/NHERF1-dependent internalization through the receptor's PDZ-binding C-tail [PMID:15665114, PMID:22610101]. In microglia, P2RY12 directs process chemotaxis toward ADP/ATP gradients and underlies blood–brain barrier closure, PANX1-coupled neurovascular regulation, NF-κB/NLRP3 inflammasome-driven cytokine production, p38 MAPK-dependent neuropathic pain, and modulation of neuronal excitability and general anesthesia sensitivity [PMID:18337420, PMID:26755608, PMID:31549730, PMID:31426845, PMID:34489419, PMID:37167975]. In vascular smooth muscle cells it promotes senescence via sustained Ras activation and foam-cell formation by suppressing PI3K-AKT-mTOR-dependent autophagy, and in kidney macrophages it drives TGF-β/Smad3-mediated macrophage-to-myofibroblast transition [PMID:32160082, PMID:27534720, PMID:35791881]. A dominant-negative ECL3 variant (R265P) that disrupts receptor homodimerization and signaling has been identified in a patient family, linking P2RY12 dysfunction to impaired platelet aggregation [PMID:29117459].","teleology":[{"year":2000,"claim":"Establishing that an orphan Gi-coupled receptor is the ADP target answered what receptor mediates ADP-driven inhibition of platelet adenylyl cyclase.","evidence":"Heterologous expression in CHO cells with adenylyl cyclase and Ca2+ assays plus mass-spectrometric ligand identification","pmids":["11104774"],"confidence":"High","gaps":["G protein subtype selectivity not yet defined","downstream effectors beyond cyclase not addressed"]},{"year":2003,"claim":"Reconstitution with purified components defined G protein selectivity and confirmed the receptor as the pharmacological P2T/P2TAC and clopidogrel target.","evidence":"Sf9 expression, purification and lipid-vesicle reconstitution with Gα subunits; covalent binding of clopidogrel active metabolite in transfected CHO cells and platelets","pmids":["14573771","15199474"],"confidence":"High","gaps":["physiological relevance of RGS4 enhancement not tested in vivo","covalent binding site on receptor not mapped"]},{"year":2004,"claim":"Pharmacological dissection separated Gi-dependent PI3K/Akt-MAPK proliferative signaling from Gi-independent RhoA/Rho-kinase actin remodeling, defining bifurcated downstream outputs.","evidence":"Stable CHO expression with pertussis toxin, PI3K and Rho-kinase inhibitors, proliferation and actin imaging readouts","pmids":["14717977"],"confidence":"Medium","gaps":["single cell system, not validated in primary cells","mechanism of Gi-independent RhoA coupling unresolved"]},{"year":2005,"claim":"Identifying GRK2/GRK6 rather than PKC as the desensitizing kinases explained how P2Y12 signaling is terminated and distinguished it from P2Y1.","evidence":"Dominant-negative GRK mutants and siRNA in 1321N1 cells, platelet desensitization assays","pmids":["15665114"],"confidence":"High","gaps":["arrestin recruitment downstream of GRK not directly demonstrated here","phosphosite mapping absent"]},{"year":2008,"claim":"Defining the DAG-kinase suppression mechanism showed how Gi-coupled P2Y12 amplifies Gq-driven PKC/Rap1b signaling in platelets, explaining its co-activation role.","evidence":"Human platelet aggregation, pleckstrin phosphorylation, Rap1b activation, DGK inhibition and phorbol ester bypass","pmids":["18755689"],"confidence":"High","gaps":["DGK isoform involved not identified","link to RhoA pathway not addressed"]},{"year":2008,"claim":"Placing P2Y12 upstream of microglial p38 MAPK established a CNS signaling axis driving neuropathic pain, extending the receptor's role beyond platelets.","evidence":"Rat sciatic nerve ligation, in situ hybridization, intrathecal antagonist/antisense, agonist mimicry, p-p38 Western blot","pmids":["18337420"],"confidence":"High","gaps":["direct biochemical link from P2Y12 to p38 not reconstituted","cell-autonomy within microglia not isolated"]},{"year":2010,"claim":"Epistasis with PAR knockouts positioned P2Y12 as a thrombin/PAR-independent amplifier in hemostasis and downstream of PARs in arterial thrombosis.","evidence":"P2ry12-/- and PAR-knockout mice, ex vivo aggregation, carotid thrombosis and intravital microscopy","pmids":["20930120"],"confidence":"Medium","gaps":["molecular crosstalk between PAR and P2Y12 pathways not defined","single lab"]},{"year":2012,"claim":"Genetic knockout revealed P2Y12 as the primary ADP receptor driving Rap1-dependent osteoclast resorption, broadening function to bone biology.","evidence":"P2ry12-/- mice, bone resorption and RAP1 assays, multiple in vivo osteolysis models, clopidogrel validation","pmids":["22996695"],"confidence":"High","gaps":["effector linking Rap1 to integrin/adhesion not fully mapped","human osteoclast relevance untested"]},{"year":2012,"claim":"Mapping the NHERF1/arrestin ternary complex on the receptor C-tail explained the trafficking mechanism for agonist-induced internalization.","evidence":"Co-IP, internalization assays, PDZ-motif mutant constructs and in vitro binding","pmids":["22610101"],"confidence":"Medium","gaps":["single lab without reciprocal in vivo validation","fate of internalized receptor not tracked"]},{"year":2014,"claim":"High-resolution crystal structures in antagonist- and agonist-bound states defined the ligand-binding architecture and the unprecedented extracellular rearrangement required for agonist access.","evidence":"X-ray crystallography of AZD1283-, 2MeSADP- and 2MeSATP-bound human P2Y12R with docking","pmids":["24670650","24784220"],"confidence":"High","gaps":["no active-state G-protein-bound structure","dynamics of disulfide and helix V not captured in solution"]},{"year":2015,"claim":"Showing M2-polarization-associated P2Y12 upregulation and neuronal cAMP/ryanodine-coupled Ca2+ signaling extended the receptor's signaling repertoire across CNS cell types.","evidence":"Human microglia M1/M2 cultures with calcium imaging and migration assays; rat trigeminal neuron calcium imaging with pharmacological dissection","pmids":["25821842","25987295"],"confidence":"Medium","gaps":["in vivo relevance of M2 upregulation untested","neuronal P2Y12 expression contribution versus microglial unclear"]},{"year":2016,"claim":"Live imaging tied microglial P2RY12-mediated chemotaxis to blood–brain barrier closure, establishing a vascular-protective CNS function.","evidence":"Two-photon imaging in P2RY12-/- and clopidogrel-treated mice after laser-induced BBB breakdown","pmids":["26755608"],"confidence":"High","gaps":["molecular effectors of process motility not defined","relationship to inflammatory signaling unaddressed"]},{"year":2016,"claim":"Two vascular smooth muscle studies established P2Y12 as a driver of foam-cell formation via PI3K-AKT-mTOR autophagy suppression and of senescence via sustained Ras activation.","evidence":"ApoE-/- and stretch models, siRNA and pharmacological inhibition, phosphoproteomics, ATG5/mTOR epistasis, Ras activation assays; P2ry12-/- mice","pmids":["32160082","27534720"],"confidence":"High","gaps":["link between ADP source and chronic receptor activation in vivo incomplete","whether Ras and mTOR arms are connected unknown"]},{"year":2017,"claim":"A patient-derived dominant-negative ECL3 variant (R265P) revealed that homodimerization is required for receptor function and links P2Y12 defects to a bleeding phenotype.","evidence":"Family sequencing, mutant overexpression, surface expression and Gi signaling assays, dominant-negative co-expression, platelet aggregometry","pmids":["29117459"],"confidence":"Medium","gaps":["structural basis of dimer interface not directly resolved","single family/lab"]},{"year":2019,"claim":"Microglial knockout work connected P2Y12 to NF-κB/NLRP3 inflammasome-driven cytokine output and to regulation of hippocampal neuronal excitability and innate fear.","evidence":"P2Y12-deficient microglia with siRNA and antagonist, NF-κB reporter/cytokine ELISA/caspase-1; constitutive and inducible conditional knockouts with behavior, c-fos and patch clamp","pmids":["31549730","31426845"],"confidence":"High","gaps":["mechanism coupling P2Y12 to NLRP3 priming versus activation unclear","how microglial signaling alters neuronal excitability not defined molecularly"]},{"year":2021,"claim":"Studies defined a PANX1-P2RY12 axis for neurovascular regulation and showed NOD2-driven P2Y12 upregulation underlies platelet hyperactivity in sepsis.","evidence":"P2RY12-/- and PANX1-/- mice with two-photon imaging and blood-flow measures; septic patient and CLP platelets, NOD2-/- mice, pAkt/pVASP readouts","pmids":["34489419","34748820"],"confidence":"High","gaps":["purine species and source linking PANX1 to P2RY12 not fully resolved","transcriptional control of P2Y12 in platelets versus inheritance unclear"]},{"year":2022,"claim":"Convergent studies extended P2Y12 to TGF-β/Smad3-driven macrophage-to-myofibroblast transition in renal fibrosis and to platelet CD40L-dependent anti-tumor CD8+ T cell responses.","evidence":"LysM lineage tracing, UUO model, scRNA-seq, siRNA/clopidogrel and Smad3 analysis; P2Y12 depletion with WT versus CD40L-/- platelet transfusion in NAFLD-HCC models","pmids":["35791881","36055226"],"confidence":"Medium","gaps":["direct receptor-to-Smad3 coupling mechanism not reconstituted","single-lab findings for each context"]},{"year":2023,"claim":"Microglial studies linked P2Y12 to Arp2-dependent podosome/filopodia-mediated Tau degradation and to control of general anesthesia depth, broadening its CNS effector and behavioral roles.","evidence":"N9 microglia imaging with actin scaffold colocalization and antagonist; microglial conditional knockout, depletion/repopulation and chemogenetics with anesthesia behavioral readouts and scRNA-seq","pmids":["37221563","37167975"],"confidence":"High","gaps":["molecular link from P2Y12 to Arp2/podosome machinery not defined","how microglial P2Y12 influences anesthetic targets mechanistically unknown"]},{"year":null,"claim":"How a single Gαi-coupled receptor is wired to such divergent effector outputs (Ras, mTOR-autophagy, Smad3, NLRP3, RhoA, podosome assembly) in a cell-type-specific manner, and how its active-state G-protein-coupled conformation is structured, remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["no active-state ternary (receptor–G protein) structure","cell-type-specific determinants of effector selection unknown","direct biochemical links between receptor and several downstream pathways not reconstituted"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,4,5]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[5,22]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[14,23,17]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[12]}],"complexes":["P2Y12 homodimer"],"partners":["NHERF1","GRK2","GRK6","ARRB (ARRESTIN)","PANX1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H244","full_name":"P2Y purinoceptor 12","aliases":["ADP-glucose receptor","ADPG-R","P2T(AC)","P2Y(AC)","P2Y(cyc)","P2Y12 platelet ADP receptor","P2Y(ADP)","SP1999"],"length_aa":342,"mass_kda":39.4,"function":"Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9H244/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/P2RY12","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/P2RY12","total_profiled":1310},"omim":[{"mim_id":"618872","title":"NIZON-ISIDOR SYNDROME; NIZIDS","url":"https://www.omim.org/entry/618872"},{"mim_id":"611318","title":"MEDIATOR COMPLEX SUBUNIT 12-LIKE; MED12L","url":"https://www.omim.org/entry/611318"},{"mim_id":"609821","title":"BLEEDING DISORDER, PLATELET-TYPE, 8; BDPLT8","url":"https://www.omim.org/entry/609821"},{"mim_id":"607367","title":"POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 13; KCNK13","url":"https://www.omim.org/entry/607367"},{"mim_id":"603071","title":"G PROTEIN-COUPLED RECEPTOR 17; GPR17","url":"https://www.omim.org/entry/603071"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":41.9}],"url":"https://www.proteinatlas.org/search/P2RY12"},"hgnc":{"alias_symbol":["P2Y12","SP1999","HORK3"],"prev_symbol":[]},"alphafold":{"accession":"Q9H244","domains":[{"cath_id":"1.20.1070.10","chopping":"24-307","consensus_level":"high","plddt":90.886,"start":24,"end":307}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H244","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H244-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H244-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=P2RY12","jax_strain_url":"https://www.jax.org/strain/search?query=P2RY12"},"sequence":{"accession":"Q9H244","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H244.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H244/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H244"}},"corpus_meta":[{"pmid":"24670650","id":"PMC_24670650","title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24670650","citation_count":317,"is_preprint":false},{"pmid":"29084738","id":"PMC_29084738","title":"International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/29084738","citation_count":307,"is_preprint":false},{"pmid":"26755608","id":"PMC_26755608","title":"Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26755608","citation_count":282,"is_preprint":false},{"pmid":"19604248","id":"PMC_19604248","title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.","date":"2009","source":"Cardiovascular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19604248","citation_count":271,"is_preprint":false},{"pmid":"24784220","id":"PMC_24784220","title":"Agonist-bound structure of the human P2Y12 receptor.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24784220","citation_count":265,"is_preprint":false},{"pmid":"18337420","id":"PMC_18337420","title":"P2Y12 receptor upregulation in activated microglia is a gateway of p38 signaling and neuropathic pain.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18337420","citation_count":247,"is_preprint":false},{"pmid":"15852221","id":"PMC_15852221","title":"Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.","date":"2005","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/15852221","citation_count":246,"is_preprint":false},{"pmid":"34489419","id":"PMC_34489419","title":"Capillary-associated microglia regulate vascular structure and function through PANX1-P2RY12 coupling in mice.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34489419","citation_count":240,"is_preprint":false},{"pmid":"14603465","id":"PMC_14603465","title":"Selective expression of Gi/o-coupled ATP receptor P2Y12 in microglia in rat brain.","date":"2003","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/14603465","citation_count":197,"is_preprint":false},{"pmid":"11104774","id":"PMC_11104774","title":"ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11104774","citation_count":168,"is_preprint":false},{"pmid":"32160082","id":"PMC_32160082","title":"The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32160082","citation_count":161,"is_preprint":false},{"pmid":"33561958","id":"PMC_33561958","title":"Microglia and Neuroinflammation: What Place for P2RY12?","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33561958","citation_count":158,"is_preprint":false},{"pmid":"25821842","id":"PMC_25821842","title":"P2Y12 expression and function in alternatively activated human microglia.","date":"2015","source":"Neurology(R) neuroimmunology & neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25821842","citation_count":154,"is_preprint":false},{"pmid":"16611109","id":"PMC_16611109","title":"Biology and pharmacology of the platelet P2Y12 receptor.","date":"2006","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/16611109","citation_count":146,"is_preprint":false},{"pmid":"26283269","id":"PMC_26283269","title":"Switching P2Y12-receptor inhibitors in patients with coronary artery disease.","date":"2015","source":"Nature reviews. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26283269","citation_count":145,"is_preprint":false},{"pmid":"20966167","id":"PMC_20966167","title":"The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20966167","citation_count":137,"is_preprint":false},{"pmid":"35247551","id":"PMC_35247551","title":"Co-expression patterns of microglia markers Iba1, TMEM119 and P2RY12 in Alzheimer's disease.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35247551","citation_count":136,"is_preprint":false},{"pmid":"15665114","id":"PMC_15665114","title":"P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15665114","citation_count":133,"is_preprint":false},{"pmid":"26149010","id":"PMC_26149010","title":"P2Y12 receptors: structure and function.","date":"2015","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/26149010","citation_count":130,"is_preprint":false},{"pmid":"24262612","id":"PMC_24262612","title":"Response variability to P2Y12 receptor inhibitors: expectations and reality.","date":"2013","source":"JACC. Cardiovascular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/24262612","citation_count":128,"is_preprint":false},{"pmid":"25904241","id":"PMC_25904241","title":"Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.","date":"2015","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/25904241","citation_count":113,"is_preprint":false},{"pmid":"26576724","id":"PMC_26576724","title":"Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain.","date":"2015","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26576724","citation_count":108,"is_preprint":false},{"pmid":"31968618","id":"PMC_31968618","title":"Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer's Disease Brains.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31968618","citation_count":107,"is_preprint":false},{"pmid":"24114622","id":"PMC_24114622","title":"Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.","date":"2013","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24114622","citation_count":105,"is_preprint":false},{"pmid":"22528678","id":"PMC_22528678","title":"P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.","date":"2012","source":"Purinergic signalling","url":"https://pubmed.ncbi.nlm.nih.gov/22528678","citation_count":105,"is_preprint":false},{"pmid":"26758983","id":"PMC_26758983","title":"Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.","date":"2016","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26758983","citation_count":91,"is_preprint":false},{"pmid":"22183178","id":"PMC_22183178","title":"P2Y12 platelet inhibition in clinical practice.","date":"2012","source":"Journal of thrombosis and thrombolysis","url":"https://pubmed.ncbi.nlm.nih.gov/22183178","citation_count":89,"is_preprint":false},{"pmid":"11454254","id":"PMC_11454254","title":"The P2Y12 receptor as a therapeutic target in cardiovascular disease.","date":"2001","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/11454254","citation_count":89,"is_preprint":false},{"pmid":"31426845","id":"PMC_31426845","title":"Microglial P2Y12 receptor regulates ventral hippocampal CA1 neuronal excitability and innate fear in mice.","date":"2019","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/31426845","citation_count":87,"is_preprint":false},{"pmid":"27055904","id":"PMC_27055904","title":"P2Y12 Receptor Modulates Sepsis-Induced Inflammation.","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27055904","citation_count":86,"is_preprint":false},{"pmid":"22996695","id":"PMC_22996695","title":"The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22996695","citation_count":86,"is_preprint":false},{"pmid":"26156883","id":"PMC_26156883","title":"Effect of P2Y12 inhibitors on inflammation and immunity.","date":"2015","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/26156883","citation_count":85,"is_preprint":false},{"pmid":"32092903","id":"PMC_32092903","title":"P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32092903","citation_count":83,"is_preprint":false},{"pmid":"25209096","id":"PMC_25209096","title":"Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery.","date":"2014","source":"British journal of anaesthesia","url":"https://pubmed.ncbi.nlm.nih.gov/25209096","citation_count":80,"is_preprint":false},{"pmid":"35791881","id":"PMC_35791881","title":"P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35791881","citation_count":77,"is_preprint":false},{"pmid":"15199474","id":"PMC_15199474","title":"P2Y12, a new platelet ADP receptor, target of clopidogrel.","date":"2003","source":"Seminars in vascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15199474","citation_count":77,"is_preprint":false},{"pmid":"21231822","id":"PMC_21231822","title":"P2Y12 receptor in platelet activation.","date":"2011","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/21231822","citation_count":76,"is_preprint":false},{"pmid":"24971933","id":"PMC_24971933","title":"Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents.","date":"2014","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/24971933","citation_count":74,"is_preprint":false},{"pmid":"27975100","id":"PMC_27975100","title":"Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus.","date":"2016","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/27975100","citation_count":72,"is_preprint":false},{"pmid":"31597724","id":"PMC_31597724","title":"Microglial P2Y12 Receptor Regulates Seizure-Induced Neurogenesis and Immature Neuronal Projections.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31597724","citation_count":71,"is_preprint":false},{"pmid":"36055226","id":"PMC_36055226","title":"Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD.","date":"2022","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/36055226","citation_count":67,"is_preprint":false},{"pmid":"17111196","id":"PMC_17111196","title":"Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts.","date":"2006","source":"Journal of thrombosis and thrombolysis","url":"https://pubmed.ncbi.nlm.nih.gov/17111196","citation_count":67,"is_preprint":false},{"pmid":"14573771","id":"PMC_14573771","title":"Purification and functional reconstitution of the human P2Y12 receptor.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14573771","citation_count":65,"is_preprint":false},{"pmid":"28073370","id":"PMC_28073370","title":"Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade.","date":"2017","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/28073370","citation_count":65,"is_preprint":false},{"pmid":"19783848","id":"PMC_19783848","title":"P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis.","date":"2009","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/19783848","citation_count":62,"is_preprint":false},{"pmid":"33644757","id":"PMC_33644757","title":"Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor.","date":"2021","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/33644757","citation_count":60,"is_preprint":false},{"pmid":"26353776","id":"PMC_26353776","title":"Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26353776","citation_count":59,"is_preprint":false},{"pmid":"14597584","id":"PMC_14597584","title":"Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.","date":"2003","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/14597584","citation_count":59,"is_preprint":false},{"pmid":"31549730","id":"PMC_31549730","title":"Extracellular ADP augments microglial inflammasome and NF-κB activation via the P2Y12 receptor.","date":"2019","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31549730","citation_count":56,"is_preprint":false},{"pmid":"14717977","id":"PMC_14717977","title":"Gi-dependent and -independent mechanisms downstream of the P2Y12 ADP-receptor.","date":"2004","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/14717977","citation_count":52,"is_preprint":false},{"pmid":"32056160","id":"PMC_32056160","title":"Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists.","date":"2020","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/32056160","citation_count":50,"is_preprint":false},{"pmid":"24845219","id":"PMC_24845219","title":"The role of P2Y₁₂ receptor and activated platelets during inflammation.","date":"2014","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/24845219","citation_count":50,"is_preprint":false},{"pmid":"29456511","id":"PMC_29456511","title":"P2Y12 Receptors in Tumorigenesis and Metastasis.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29456511","citation_count":50,"is_preprint":false},{"pmid":"18755689","id":"PMC_18755689","title":"The Gi-coupled P2Y12 receptor regulates diacylglycerol-mediated signaling in human platelets.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18755689","citation_count":48,"is_preprint":false},{"pmid":"30291899","id":"PMC_30291899","title":"Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery.","date":"2018","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/30291899","citation_count":47,"is_preprint":false},{"pmid":"24406062","id":"PMC_24406062","title":"Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.","date":"2014","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/24406062","citation_count":47,"is_preprint":false},{"pmid":"24763899","id":"PMC_24763899","title":"Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.","date":"2014","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/24763899","citation_count":45,"is_preprint":false},{"pmid":"28204303","id":"PMC_28204303","title":"Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.","date":"2017","source":"European heart journal. Cardiovascular pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/28204303","citation_count":39,"is_preprint":false},{"pmid":"20930120","id":"PMC_20930120","title":"Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20930120","citation_count":39,"is_preprint":false},{"pmid":"15464998","id":"PMC_15464998","title":"Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15464998","citation_count":37,"is_preprint":false},{"pmid":"26677375","id":"PMC_26677375","title":"Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.","date":"2015","source":"Postepy w kardiologii interwencyjnej = Advances in interventional cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26677375","citation_count":36,"is_preprint":false},{"pmid":"21261805","id":"PMC_21261805","title":"Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia.","date":"2011","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/21261805","citation_count":36,"is_preprint":false},{"pmid":"21479343","id":"PMC_21479343","title":"Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.","date":"2011","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/21479343","citation_count":36,"is_preprint":false},{"pmid":"27534720","id":"PMC_27534720","title":"Sustained activation of ADP/P2ry12 signaling induces SMC senescence contributing to thoracic aortic aneurysm/dissection.","date":"2016","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27534720","citation_count":35,"is_preprint":false},{"pmid":"34589424","id":"PMC_34589424","title":"P2RY12-Inhibitors Reduce Cancer-Associated Thrombosis and Tumor Growth in Pancreatic Cancers.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34589424","citation_count":34,"is_preprint":false},{"pmid":"30302530","id":"PMC_30302530","title":"The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/30302530","citation_count":32,"is_preprint":false},{"pmid":"20124464","id":"PMC_20124464","title":"Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.","date":"2010","source":"The Annals of pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/20124464","citation_count":32,"is_preprint":false},{"pmid":"33142937","id":"PMC_33142937","title":"Inhibiting P2Y12 in Macrophages Induces Endoplasmic Reticulum Stress and Promotes an Anti-Tumoral Phenotype.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33142937","citation_count":32,"is_preprint":false},{"pmid":"25987295","id":"PMC_25987295","title":"Expression and function of purinergic P2Y12 receptors in rat trigeminal ganglion neurons.","date":"2015","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/25987295","citation_count":31,"is_preprint":false},{"pmid":"22610101","id":"PMC_22610101","title":"Arrestin scaffolds NHERF1 to the P2Y12 receptor to regulate receptor internalization.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22610101","citation_count":31,"is_preprint":false},{"pmid":"37167975","id":"PMC_37167975","title":"Microglia modulate general anesthesia through P2Y12 receptor.","date":"2023","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/37167975","citation_count":29,"is_preprint":false},{"pmid":"21946947","id":"PMC_21946947","title":"BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.","date":"2011","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/21946947","citation_count":28,"is_preprint":false},{"pmid":"27628007","id":"PMC_27628007","title":"Role of P2Y12 Receptor in Thrombosis.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/27628007","citation_count":27,"is_preprint":false},{"pmid":"23356287","id":"PMC_23356287","title":"Molecular mechanisms of platelet P2Y(12) receptor regulation.","date":"2013","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/23356287","citation_count":27,"is_preprint":false},{"pmid":"22010907","id":"PMC_22010907","title":"Gene-by-environment effect of house dust mite on purinergic receptor P2Y12 (P2RY12) and lung function in children with asthma.","date":"2012","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22010907","citation_count":27,"is_preprint":false},{"pmid":"34319489","id":"PMC_34319489","title":"The Function and Regulation of Platelet P2Y12 Receptor.","date":"2021","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34319489","citation_count":26,"is_preprint":false},{"pmid":"28921447","id":"PMC_28921447","title":"Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor.","date":"2017","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/28921447","citation_count":26,"is_preprint":false},{"pmid":"37047682","id":"PMC_37047682","title":"The Signaling Pathway of the ADP Receptor P2Y12 in the Immune System: Recent Discoveries and New Challenges.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37047682","citation_count":26,"is_preprint":false},{"pmid":"37221563","id":"PMC_37221563","title":"Microglia degrade Tau oligomers deposit via purinergic P2Y12-associated podosome and filopodia formation and induce chemotaxis.","date":"2023","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/37221563","citation_count":26,"is_preprint":false},{"pmid":"29916540","id":"PMC_29916540","title":"Montelukast inhibits RANKL‑induced osteoclast formation and bone loss via CysLTR1 and P2Y12.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29916540","citation_count":26,"is_preprint":false},{"pmid":"36630990","id":"PMC_36630990","title":"P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions.","date":"2023","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/36630990","citation_count":25,"is_preprint":false},{"pmid":"26448282","id":"PMC_26448282","title":"Purinergic P2Y12 Receptor Activation in Eosinophils and the Schistosomal Host Response.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26448282","citation_count":25,"is_preprint":false},{"pmid":"26561399","id":"PMC_26561399","title":"P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation.","date":"2016","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26561399","citation_count":24,"is_preprint":false},{"pmid":"31434806","id":"PMC_31434806","title":"Targetable purinergic receptors P2Y12 and A2b antagonistically regulate bladder function.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31434806","citation_count":23,"is_preprint":false},{"pmid":"37061007","id":"PMC_37061007","title":"Tau aggregates improve the Purinergic receptor P2Y12-associated podosome rearrangements in microglial cells.","date":"2023","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37061007","citation_count":23,"is_preprint":false},{"pmid":"17110146","id":"PMC_17110146","title":"Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.","date":"2006","source":"Journal of molecular graphics & modelling","url":"https://pubmed.ncbi.nlm.nih.gov/17110146","citation_count":23,"is_preprint":false},{"pmid":"36588476","id":"PMC_36588476","title":"Pharmacogenetics of P2Y12 receptor inhibitors.","date":"2023","source":"Pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/36588476","citation_count":22,"is_preprint":false},{"pmid":"27586412","id":"PMC_27586412","title":"P2Y12 Receptor Antagonists and Morphine: A Dangerous Liaison?","date":"2016","source":"Circulation. Cardiovascular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/27586412","citation_count":22,"is_preprint":false},{"pmid":"19678800","id":"PMC_19678800","title":"Platelet P2Y12 receptor inhibition by thienopyridines: status and future.","date":"2009","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/19678800","citation_count":22,"is_preprint":false},{"pmid":"38518636","id":"PMC_38518636","title":"Gualou-Xiebai herb pair and its active ingredients act against atherosclerosis by suppressing VSMC-derived foam cell formation via regulating P2RY12-mediated lipophagy.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38518636","citation_count":21,"is_preprint":false},{"pmid":"37771103","id":"PMC_37771103","title":"The role of platelet P2Y12 receptors in inflammation.","date":"2023","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37771103","citation_count":21,"is_preprint":false},{"pmid":"17355284","id":"PMC_17355284","title":"Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells.","date":"2007","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/17355284","citation_count":21,"is_preprint":false},{"pmid":"27231519","id":"PMC_27231519","title":"P2Y12-ADP receptor antagonists: Days of future and past.","date":"2016","source":"World journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27231519","citation_count":20,"is_preprint":false},{"pmid":"29117459","id":"PMC_29117459","title":"Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding.","date":"2017","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/29117459","citation_count":20,"is_preprint":false},{"pmid":"34748820","id":"PMC_34748820","title":"NOD2-mediated P2Y12 upregulation increases platelet activation and thrombosis in sepsis.","date":"2021","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34748820","citation_count":19,"is_preprint":false},{"pmid":"19604122","id":"PMC_19604122","title":"Cangrelor: a novel P2Y12 receptor antagonist.","date":"2009","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/19604122","citation_count":18,"is_preprint":false},{"pmid":"26444255","id":"PMC_26444255","title":"Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.","date":"2016","source":"Coronary artery disease","url":"https://pubmed.ncbi.nlm.nih.gov/26444255","citation_count":18,"is_preprint":false},{"pmid":"28383427","id":"PMC_28383427","title":"Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome.","date":"2017","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28383427","citation_count":17,"is_preprint":false},{"pmid":"25106522","id":"PMC_25106522","title":"Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25106522","citation_count":15,"is_preprint":false},{"pmid":"29338536","id":"PMC_29338536","title":"P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosis.","date":"2018","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29338536","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51404,"output_tokens":7661,"usd":0.134564,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17147,"output_tokens":5749,"usd":0.11473,"stage2_stop_reason":"end_turn"},"total_usd":0.249294,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"SP1999 (P2RY12) is a Gαi-coupled receptor for ADP; ADP inhibits forskolin-stimulated adenylyl cyclase activity through selective activation of this receptor with an EC50 of 60 nM. The rank order of potency was 2-MeS-ATP = 2-MeS-ADP > ADP > other nucleotides. ATP showed no agonist activity but acted as a low-affinity antagonist.\",\n      \"method\": \"Heterologous expression in CHO cells, adenylyl cyclase inhibition assay, Ca2+ mobilization assay with chimeric Gαq/i, mass spectrometry identification of purified ligand from rat spinal cord extracts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in transfected cells with multiple orthogonal methods (functional assay, ligand purification and MS identification, pharmacological profiling), single rigorous paper\",\n      \"pmids\": [\"11104774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Purified recombinant human P2Y12 receptor couples most robustly to Gαi2, and also effectively to Gαi1 and Gαi3, but shows little or no coupling to Gαo or Gαq. 2MeSADP is the most potent agonist (EC50 = 80 nM); ADP is ~1000-fold less potent. ATP acts as a low-affinity antagonist. RGS4 markedly enhances agonist-stimulated GTPase activity.\",\n      \"method\": \"Baculovirus expression in Sf9 cells, protein purification, reconstitution in lipid vesicles with purified Gα subunits and Gβ1γ2, steady-state GTPase assay\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified components, multiple G protein subunit combinations tested, rigorous functional assay\",\n      \"pmids\": [\"14573771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The active metabolite of clopidogrel binds covalently and irreversibly to P2Y12 on platelets and in stably transfected CHO cells, blocking 33P-2MeS-ADP binding and ADP-induced adenylyl cyclase downregulation. P2Y12 corresponds to the previously designated 'P2T/P2TAC' receptor.\",\n      \"method\": \"Stable expression in CHO cells, radioligand binding assay (33P-2MeS-ADP), adenylyl cyclase inhibition assay, pharmacological profiling with clopidogrel active metabolite\",\n      \"journal\": \"Seminars in vascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and functional assay in transfected cells, consistent with earlier published work, single lab review summarizing original findings\",\n      \"pmids\": [\"15199474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"P2Y12 desensitization is mediated by G protein-coupled receptor kinases (GRK2 and GRK6), but not by protein kinase C. This is distinct from P2Y1, whose desensitization is largely dependent on PKC activity. Both GRKs are endogenously expressed in platelets.\",\n      \"method\": \"Transient overexpression of dominant-negative GRK mutants and siRNA knockdown in 1321N1 cells; platelet aggregation desensitization assays in human platelets\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dominant-negative mutants and siRNA knockdown as orthogonal approaches in two cell systems, clearly distinguishes mechanism from P2Y1\",\n      \"pmids\": [\"15665114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"P2Y12 receptor activation in CHO cells triggers two distinct signaling pathways: (1) Gi-dependent activation of PI3-kinase/Akt upstream of MAP-kinases leading to cell proliferation, with partial contribution via transactivation of PDGF-Rβ; (2) Gi-independent RhoA/Rho-kinase activation leading to actin cytoskeleton reorganization. Both pathways are blocked by the active metabolite of clopidogrel.\",\n      \"method\": \"Stable expression in CHO cells, pharmacological inhibition (pertussis toxin, PI3K inhibitors, Rho-kinase inhibitors), cell proliferation assays, actin cytoskeleton imaging\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological dissection approaches in single cell system, two orthogonal readouts (proliferation vs. actin), single lab\",\n      \"pmids\": [\"14717977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The Gi-coupled P2Y12 receptor regulates diacylglycerol (DAG)-mediated signaling in platelets: P2Y12 stimulation inhibits diacylglycerol kinase-mediated phosphorylation of DAG to phosphatidic acid, thereby sustaining DAG levels and enhancing PKC activation and Rap1b activation downstream of Gq-coupled receptors. This effect requires PI3-kinase rather than adenylyl cyclase inhibition.\",\n      \"method\": \"Platelet aggregation assays, pleckstrin phosphorylation (PKC readout), Rap1b activation assay, diacylglycerol kinase inhibition, pharmacological blockade of P2Y1 and P2Y12 receptors, phorbol ester bypass experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal pharmacological tools and functional readouts in human platelets, mechanistic dissection of DAG/PKC pathway, single rigorous paper\",\n      \"pmids\": [\"18755689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"P2Y12 mRNA and protein are upregulated in spinal cord microglia following partial sciatic nerve ligation, peaking at day 3. P2Y12 activation by ADP/hydrolyzed ATP acts as a gateway for p38 MAPK phosphorylation in spinal microglia; intrathecal P2Y12 antagonist or antisense knockdown suppressed p38 activation and neuropathic pain behaviors. Intrathecal P2Y12 agonist in naive rats mimicked nerve injury-induced p38 activation.\",\n      \"method\": \"Rat partial sciatic nerve ligation model, double-label in situ hybridization/immunohistochemistry, intrathecal pharmacological blockade, antisense knockdown, Western blot for p-p38\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — antisense knockdown and pharmacological blockade with consistent phenotypes, agonist mimicry experiment, mechanistic pathway placement (P2Y12→p38 MAPK), single rigorous study\",\n      \"pmids\": [\"18337420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"P2RY12 is the primary ADP receptor in osteoclasts (OCs). ADP stimulation of P2RY12 activates RAP1 and enhances OC adhesion and bone resorptive activity. P2ry12-/- OCs show intact differentiation but diminished resorptive function and blunted ADP-induced RAP1 activation. P2ry12-/- mice are partially protected from age-associated bone loss, arthritis-induced osteolysis, tumor-induced osteolysis, and ovariectomy-induced osteoporosis.\",\n      \"method\": \"P2ry12-/- mice, bone resorption assays, RAP1 activation assay, integrin β3 knockout comparison, in vivo bone loss models (FeCl3 arthritis, tumor, ovariectomy), clopidogrel pharmacological treatment\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple in vivo disease models, RAP1 signaling assay, pharmacological validation, multiple orthogonal approaches\",\n      \"pmids\": [\"22996695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"P2Y12 receptor internalization requires interaction of its PDZ-binding motif with NHERF1. Prior to agonist stimulation, NHERF1 binds directly to the receptor C-tail. Upon agonist stimulation, NHERF1 no longer binds the receptor directly but instead interacts via arrestin as a scaffold, promoting NHERF1-dependent receptor internalization.\",\n      \"method\": \"Co-immunoprecipitation, mammalian cell overexpression, receptor internalization assays, dominant-negative and mutant receptor constructs, in vitro binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and functional internalization assay with mutant constructs, mechanistic model of arrestin-NHERF1-receptor ternary complex, single lab\",\n      \"pmids\": [\"22610101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structure of human P2Y12R at 2.6 Å resolution in complex with antagonist AZD1283 reveals: (1) a distinct straight conformation of helix V unique among class A GPCRs; (2) absence of the conserved disulfide bridge between helix III and ECL2 (appears dynamic); (3) a non-nucleotide ligand-binding site with an adjacent pocket suggesting both pockets are required for dinucleotide binding.\",\n      \"method\": \"X-ray crystallography at 2.6 Å resolution\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure, unique structural features experimentally defined, published in Nature\",\n      \"pmids\": [\"24670650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structures of human P2Y12R bound to full agonist 2MeSADP (2.5 Å) and partial agonist 2MeSATP (3.1 Å) reveal large-scale conformational rearrangements in the extracellular region required for agonist access to the binding pocket — the first example of such rearrangement for a GPCR. Agonist and non-nucleotide antagonist (AZD1283) adopt different orientations with only partially overlapping binding pockets.\",\n      \"method\": \"X-ray crystallography at 2.5 Å and 3.1 Å resolution, docking studies, comparison with antagonist-bound structure\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two high-resolution crystal structures with functional interpretation, mechanistically defines agonist vs antagonist binding landscapes\",\n      \"pmids\": [\"24784220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"P2RY12-mediated chemotaxis of microglial processes is required for rapid closure of the blood-brain barrier following laser-induced BBB breakdown. Both pharmacological inhibition (clopidogrel) and genetic ablation of P2RY12 significantly diminished juxtavascular microglial process movement and failed to close laser-induced BBB openings.\",\n      \"method\": \"Two-photon live imaging of microglial processes in mice, laser-induced BBB opening, P2RY12 genetic knockout mice, clopidogrel pharmacological inhibition, fluorescent tracer BBB permeability assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live imaging with genetic and pharmacological convergence, specific functional readout (BBB closure), two orthogonal approaches\",\n      \"pmids\": [\"26755608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ADP activation of P2Y12 receptor in VSMCs inhibits macroautophagy via the PI3K-AKT-MTOR pathway, blocking LC3 maturation, SQSTM1 degradation, and autophagosome formation, thereby reducing cholesterol efflux and promoting foam cell formation. P2Y12 receptor inhibition promotes VSMC autophagy and cholesterol efflux in an ATG5-dependent manner.\",\n      \"method\": \"ApoE-/- mouse atherosclerosis model, siRNA knockdown and pharmacological inhibition of P2Y12R, phosphoproteomic analysis, Western blot for LC3/SQSTM1, autophagosome TEM, cholesterol efflux assay, rapamycin rescue experiment, ATG5 knockdown epistasis\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (phosphoproteomics, genetic knockdown, pharmacological inhibition, epistasis with ATG5 and mTOR), in vivo and in vitro concordance\",\n      \"pmids\": [\"32160082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Sustained ADP/P2RY12 signaling in vascular smooth muscle cells induces senescence via sustained Ras activation. Mechanical stretch increases ADP release from SMCs; P2ry12 genetic knockout in mice protects against SMC senescence, inflammation, and TAAD formation and rupture. Pharmacological Ras inhibition also protected against SMC senescence.\",\n      \"method\": \"P2ry12-/- mice, excessive mechanical stretch model, SA-β-gal staining, senescence marker Western blotting, HPLC and luciferin-luciferase ADP measurement, Ras activation assay, pharmacological Ras inhibition\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with multiple phenotypic readouts and Ras pathway placement, single lab\",\n      \"pmids\": [\"27534720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ADP acting on microglial P2Y12 receptor activates NF-κB signaling and potentiates NLRP3 inflammasome activation, leading to enhanced IL-1β and IL-6 production. Mechanistically, ADP altered mitochondrial membrane potential in combination with ATP and increased caspase-1 positive cells through P2Y12 receptor.\",\n      \"method\": \"P2Y12 receptor-deficient microglia, siRNA knockdown, PSB0739 pharmacological blockade, NF-κB reporter assay, IL-1β/IL-6 ELISA, caspase-1 flow cytometry, mitochondrial membrane potential assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deficiency and siRNA knockdown with pharmacological confirmation, mechanistic pathway placement (ADP→P2Y12→NF-κB/NLRP3→IL-1β), single lab\",\n      \"pmids\": [\"31549730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Microglial P2Y12 receptor regulates ventral hippocampal CA1 neuronal excitability and innate fear behavior. Constitutive and induced conditional P2Y12R knockout mice exhibited increased innate fear and elevated CA1 neuronal excitability (assessed by c-fos expression and whole-cell patch clamp). Microglial process chemotaxis toward ADP/ATP gradients is mediated by P2Y12R.\",\n      \"method\": \"Conditional microglial P2Y12R knockout mice (CX3CR1-Cre and CX3CR1-CreER), behavioral testing (elevated plus maze), c-fos immunostaining, whole-cell patch clamp recording in ventral hippocampus CA1\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent conditional knockout approaches (constitutive and inducible) with convergent behavioral and electrophysiological phenotypes, direct mechanistic link between microglial P2Y12R and neuronal excitability\",\n      \"pmids\": [\"31426845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"P2RY12 receptors on capillary-associated microglia (CAMs) regulate vascular structure and function under the control of purines released from pannexin-1 (PANX1) channels. P2RY12-/- and PANX1-/- mice phenocopied microglial depletion in causing capillary dilation, increased blood flow, and impaired vasodilation, establishing a PANX1-P2RY12 coupling mechanism for neurovascular regulation.\",\n      \"method\": \"P2RY12-/- and PANX1-/- mice, microglial depletion and repopulation, two-photon live imaging, blood flow measurement, ultrastructural analysis, spatio-temporal morphological characterization\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent knockout lines phenocopy each other and microglial depletion, multiple imaging modalities, functional vascular readouts\",\n      \"pmids\": [\"34489419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"P2Y12 receptor is expressed by macrophages in fibrosing kidneys (>82% of P2Y12-expressing cells are macrophage-origin); activation by TGF-β1 induces P2Y12 expression and promotes macrophage-to-myofibroblast transition (MMT) via the Smad3-dependent signaling pathway. Silencing or pharmacological inhibition of P2Y12 blocked TGF-β/Smad3-mediated MMT and progressive renal fibrosis.\",\n      \"method\": \"LysM-Cre/Rosa Tomato lineage tracing mice, UUO model, P2Y12 siRNA knockdown, clopidogrel treatment, single-cell RNA sequencing, α-SMA/CD68 co-immunostaining, in vitro TGF-β1 stimulation, Smad3 pathway analysis\",\n      \"journal\": \"Molecular therapy : the journal of the American Society of Gene Therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — lineage tracing for cell identity, genetic and pharmacological convergence, scRNA-seq pathway analysis, Smad3 mechanistic placement, in vivo and in vitro concordance\",\n      \"pmids\": [\"35791881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"P2Y12R homodimerization is critical for receptor function and signaling. A dominant negative variant R265P in extracellular loop 3 (EL3) disrupts the binding pocket conformation, reduces agonist-stimulated signaling and receptor surface loss, and acts in a dominant negative manner by impairing wild-type homodimer function. R265 is one of four residues required for receptor functional integrity.\",\n      \"method\": \"Next-generation sequencing/Sanger sequencing of patient family, mammalian cell overexpression of R265P mutant, receptor surface expression (flow cytometry/Western blot), Gi signaling assays, dominant negative co-expression experiments, platelet aggregometry, P2RY12 cDNA cloning from patients\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant negative co-expression with mechanistic interpretation of homodimerization, single lab, patient-derived validation\",\n      \"pmids\": [\"29117459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Microglial P2Y12R mediates microglial process chemotaxis toward Tau oligomers and facilitates degradation of Tau deposits via Arp2-associated podosome and filopodia formation. P2Y12 receptors colocalize with F-actin-rich podosomes and filopodia during Tau-deposit degradation. Blockage of P2Y12 signaling decreased microglial migration and Tau-deposit degradation.\",\n      \"method\": \"N9 microglia cell culture, fluorescence microscopy for actin microstructures (podosome, filopodia, uropod), P2Y12 pharmacological blockade, colocalization with Arp2/TKS5/WASP scaffold proteins, Tau oligomer treatment\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — imaging-based colocalization with pharmacological blockade, functional migration and phagocytosis readouts, single lab\",\n      \"pmids\": [\"37221563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Microglial P2Y12R mediates microglial participation in general anesthesia. Blocking P2Y12R pharmacologically or genetic ablation of P2Y12R specifically in microglia (CX3CR1-Cre) shortened duration of loss of righting reflex (unconsciousness) from multiple anesthetics and attenuated anesthesia-accompanying analgesia and hypothermia.\",\n      \"method\": \"Microglial depletion, microglial repopulation, chemogenetic activation, conditional P2Y12R knockout (CX3CR1-Cre), pharmacological P2Y12R blockade, single-cell RNA sequencing of anesthesia-affected transcriptional programs\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological convergence with multiple anesthetics, conditional knockout confirms microglial P2Y12R specificity, multiple behavioral readouts\",\n      \"pmids\": [\"37167975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Platelet P2Y12-dependent CD40L release mediates anti-tumor activity of platelets in NAFLD-associated HCC. Pharmacological inhibition or genetic depletion of P2Y12 abrogated CD40L release from platelets, reduced CD8+ T cell activation via the CD40 receptor, and accelerated HCC growth.\",\n      \"method\": \"P2Y12 genetic depletion, pharmacological inhibition, in vivo transfusion of WT vs CD40L-/- platelets, HCC tumor models in NAFLD mice, liver metastasis models\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological convergence with CD40L-/- platelet rescue experiment establishing mechanism, single lab, multiple models\",\n      \"pmids\": [\"36055226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"P2ry12 functions in thrombin/PAR-independent pathways in vivo for hemostasis models, while in arterial thrombosis models PAR signaling was dominant. P2ry12 acts downstream of PARs to amplify platelet responses to thrombin ex vivo. P2ry12+/- platelets showed partially decreased ADP responses resembling clopidogrel-treated human platelets. Par3-/-:P2ry12-/- double-mutant mice showed combined additive protection against carotid thrombosis.\",\n      \"method\": \"P2ry12-/- and PAR knockout mice, platelet aggregation assays ex vivo, carotid artery thrombosis models with varying FeCl3 injury levels, intravital microscopy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis in double-knockout mice with multiple in vivo and ex vivo models, pathway placement of P2ry12 relative to PAR signaling, single lab\",\n      \"pmids\": [\"20930120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"P2Y12 expression is increased in alternatively activated (M2) human microglia compared to resting or classically activated (M1) microglia. M2 microglia show increased ADP-induced calcium responses that are blocked by selective P2Y12 antagonism. P2Y12 antagonism decreases migratory and inflammatory responses in human microglia upon nucleotide exposure; no effects were observed in human monocytes or macrophages.\",\n      \"method\": \"In vitro human microglia activation (M1/M2 conditions), flow cytometry, calcium imaging, P2Y12 antagonist pharmacological blockade, migration assays, in situ immunohistochemistry of MS and parasitic CNS infection brain samples\",\n      \"journal\": \"Neurology(R) neuroimmunology & neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional calcium and migration assays with pharmacological blockade, in vitro and in situ convergence, single lab\",\n      \"pmids\": [\"25821842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NOD2 activation in sepsis upregulates platelet P2Y12 expression via the RIP2/NF-κB/P65 pathway, leading to constitutive P2Y12 activation (evidenced by enhanced pAkt and impaired pVASP in resting platelets) and platelet hyperactivity. NOD2 deficiency attenuated sepsis-induced platelet P2Y12 high expression, hyperactivity, and thrombosis.\",\n      \"method\": \"Septic patient platelets, CLP mouse model, NOD2-/- mice, Western blot (pAkt, pVASP as P2Y12 signaling readouts), platelet aggregation assays, NF-κB pathway analysis\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NOD2-/- genetic validation, human patient and mouse model convergence, mechanistic pathway (NOD2→RIP2→NF-κB→P2Y12) placement, single lab\",\n      \"pmids\": [\"34748820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"P2Y12 receptor activation in trigeminal ganglion neurons mediates ADP-induced intracellular Ca2+ release from ryanodine-sensitive stores via a cAMP-dependent pathway. In the absence of extracellular Ca2+, ryanodine receptor inhibitors blocked 2-MeS-ADP-induced Ca2+ increases, and adenylate cyclase inhibition mimicked agonist effects.\",\n      \"method\": \"Rat TG neuron culture, immunofluorescence, calcium imaging with selective P2Y12 antagonists, ryanodine receptor blockers, SERCA inhibitor, adenylate/phosphodiesterase inhibitors, extracellular calcium chelation\",\n      \"journal\": \"Neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with multiple inhibitors in primary neurons, cAMP→ryanodine receptor pathway placement, single lab\",\n      \"pmids\": [\"25987295\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"P2RY12 is a Gαi2-coupled GPCR (also coupling to Gαi1/Gαi3 but not Gαo/Gαq) activated by ADP that inhibits adenylyl cyclase, activates PI3K/Akt and Rap1b, regulates diacylglycerol signaling via diacylglycerol kinase suppression, and triggers RhoA/Rho-kinase-dependent actin reorganization; its structure has been resolved in agonist- and antagonist-bound states revealing large-scale extracellular rearrangements for agonist access; it undergoes GRK2/GRK6-mediated desensitization and arrestin/NHERF1-dependent internalization; on platelets it amplifies activation, granule secretion, and thrombus formation; on microglia it mediates chemotaxis toward ATP/ADP gradients, blood-brain barrier closure, PANX1-coupled neurovascular regulation, p38 MAPK-driven neuropathic pain, NF-κB/NLRP3 inflammasome activation, and modulation of neuronal excitability and anesthesia sensitivity; in vascular smooth muscle cells it promotes senescence via sustained Ras activation and foam cell formation via PI3K-AKT-MTOR-dependent autophagy suppression; and in macrophages it drives TGF-β/Smad3-mediated myofibroblast transition and in platelets mediates CD40L release for anti-tumor CD8+ T cell responses.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"P2RY12 is a Gαi-coupled G-protein-coupled receptor for ADP that suppresses adenylyl cyclase and, through this and parallel effectors, transduces purinergic signals in platelets, microglia, and vascular and immune cells [#0, #1]. Pharmacological and reconstitution studies establish it as the clopidogrel target, originally designated the platelet P2T/P2TAC receptor: the clopidogrel active metabolite binds covalently and irreversibly to abolish ADP-induced signaling, while ATP acts as a low-affinity antagonist and 2-MeS-ADP is the most potent agonist [#1, #2]. The receptor couples most robustly to Gαi2 (and to Gαi1/Gαi3 but not Gαo/Gαq), and beyond cyclase inhibition it drives two largely separable outputs — Gi-dependent PI3-kinase/Akt activation feeding MAP-kinase signaling and proliferation, and Gi-independent RhoA/Rho-kinase-dependent actin reorganization [#1, #4]. Downstream of these effectors P2RY12 sustains diacylglycerol levels by inhibiting diacylglycerol kinase to potentiate PKC and Rap1b activation, amplifying platelet responses to thrombin/PAR signaling [#5, #22], and activates Rap1 to enhance osteoclast adhesion and bone resorption [#7]. Crystal structures in antagonist-bound (AZD1283) and full/partial agonist-bound (2MeSADP/2MeSATP) states reveal a class-A-atypical straight helix V, a dynamic helix III–ECL2 disulfide, and large-scale extracellular rearrangements required for agonist access, with agonist and non-nucleotide antagonist occupying only partially overlapping pockets [#9, #10]. Receptor signaling is terminated by GRK2/GRK6-mediated desensitization and arrestin/NHERF1-dependent internalization through the receptor's PDZ-binding C-tail [#3, #8]. In microglia, P2RY12 directs process chemotaxis toward ADP/ATP gradients and underlies blood–brain barrier closure, PANX1-coupled neurovascular regulation, NF-κB/NLRP3 inflammasome-driven cytokine production, p38 MAPK-dependent neuropathic pain, and modulation of neuronal excitability and general anesthesia sensitivity [#6, #11, #14, #15, #16, #20]. In vascular smooth muscle cells it promotes senescence via sustained Ras activation and foam-cell formation by suppressing PI3K-AKT-mTOR-dependent autophagy, and in kidney macrophages it drives TGF-β/Smad3-mediated macrophage-to-myofibroblast transition [#12, #13, #17]. A dominant-negative ECL3 variant (R265P) that disrupts receptor homodimerization and signaling has been identified in a patient family, linking P2RY12 dysfunction to impaired platelet aggregation [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that an orphan Gi-coupled receptor is the ADP target answered what receptor mediates ADP-driven inhibition of platelet adenylyl cyclase.\",\n      \"evidence\": \"Heterologous expression in CHO cells with adenylyl cyclase and Ca2+ assays plus mass-spectrometric ligand identification\",\n      \"pmids\": [\"11104774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G protein subtype selectivity not yet defined\", \"downstream effectors beyond cyclase not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Reconstitution with purified components defined G protein selectivity and confirmed the receptor as the pharmacological P2T/P2TAC and clopidogrel target.\",\n      \"evidence\": \"Sf9 expression, purification and lipid-vesicle reconstitution with Gα subunits; covalent binding of clopidogrel active metabolite in transfected CHO cells and platelets\",\n      \"pmids\": [\"14573771\", \"15199474\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"physiological relevance of RGS4 enhancement not tested in vivo\", \"covalent binding site on receptor not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Pharmacological dissection separated Gi-dependent PI3K/Akt-MAPK proliferative signaling from Gi-independent RhoA/Rho-kinase actin remodeling, defining bifurcated downstream outputs.\",\n      \"evidence\": \"Stable CHO expression with pertussis toxin, PI3K and Rho-kinase inhibitors, proliferation and actin imaging readouts\",\n      \"pmids\": [\"14717977\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"single cell system, not validated in primary cells\", \"mechanism of Gi-independent RhoA coupling unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying GRK2/GRK6 rather than PKC as the desensitizing kinases explained how P2Y12 signaling is terminated and distinguished it from P2Y1.\",\n      \"evidence\": \"Dominant-negative GRK mutants and siRNA in 1321N1 cells, platelet desensitization assays\",\n      \"pmids\": [\"15665114\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"arrestin recruitment downstream of GRK not directly demonstrated here\", \"phosphosite mapping absent\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defining the DAG-kinase suppression mechanism showed how Gi-coupled P2Y12 amplifies Gq-driven PKC/Rap1b signaling in platelets, explaining its co-activation role.\",\n      \"evidence\": \"Human platelet aggregation, pleckstrin phosphorylation, Rap1b activation, DGK inhibition and phorbol ester bypass\",\n      \"pmids\": [\"18755689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DGK isoform involved not identified\", \"link to RhoA pathway not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placing P2Y12 upstream of microglial p38 MAPK established a CNS signaling axis driving neuropathic pain, extending the receptor's role beyond platelets.\",\n      \"evidence\": \"Rat sciatic nerve ligation, in situ hybridization, intrathecal antagonist/antisense, agonist mimicry, p-p38 Western blot\",\n      \"pmids\": [\"18337420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"direct biochemical link from P2Y12 to p38 not reconstituted\", \"cell-autonomy within microglia not isolated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Epistasis with PAR knockouts positioned P2Y12 as a thrombin/PAR-independent amplifier in hemostasis and downstream of PARs in arterial thrombosis.\",\n      \"evidence\": \"P2ry12-/- and PAR-knockout mice, ex vivo aggregation, carotid thrombosis and intravital microscopy\",\n      \"pmids\": [\"20930120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"molecular crosstalk between PAR and P2Y12 pathways not defined\", \"single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Genetic knockout revealed P2Y12 as the primary ADP receptor driving Rap1-dependent osteoclast resorption, broadening function to bone biology.\",\n      \"evidence\": \"P2ry12-/- mice, bone resorption and RAP1 assays, multiple in vivo osteolysis models, clopidogrel validation\",\n      \"pmids\": [\"22996695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"effector linking Rap1 to integrin/adhesion not fully mapped\", \"human osteoclast relevance untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapping the NHERF1/arrestin ternary complex on the receptor C-tail explained the trafficking mechanism for agonist-induced internalization.\",\n      \"evidence\": \"Co-IP, internalization assays, PDZ-motif mutant constructs and in vitro binding\",\n      \"pmids\": [\"22610101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"single lab without reciprocal in vivo validation\", \"fate of internalized receptor not tracked\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"High-resolution crystal structures in antagonist- and agonist-bound states defined the ligand-binding architecture and the unprecedented extracellular rearrangement required for agonist access.\",\n      \"evidence\": \"X-ray crystallography of AZD1283-, 2MeSADP- and 2MeSATP-bound human P2Y12R with docking\",\n      \"pmids\": [\"24670650\", \"24784220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"no active-state G-protein-bound structure\", \"dynamics of disulfide and helix V not captured in solution\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showing M2-polarization-associated P2Y12 upregulation and neuronal cAMP/ryanodine-coupled Ca2+ signaling extended the receptor's signaling repertoire across CNS cell types.\",\n      \"evidence\": \"Human microglia M1/M2 cultures with calcium imaging and migration assays; rat trigeminal neuron calcium imaging with pharmacological dissection\",\n      \"pmids\": [\"25821842\", \"25987295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"in vivo relevance of M2 upregulation untested\", \"neuronal P2Y12 expression contribution versus microglial unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Live imaging tied microglial P2RY12-mediated chemotaxis to blood–brain barrier closure, establishing a vascular-protective CNS function.\",\n      \"evidence\": \"Two-photon imaging in P2RY12-/- and clopidogrel-treated mice after laser-induced BBB breakdown\",\n      \"pmids\": [\"26755608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"molecular effectors of process motility not defined\", \"relationship to inflammatory signaling unaddressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Two vascular smooth muscle studies established P2Y12 as a driver of foam-cell formation via PI3K-AKT-mTOR autophagy suppression and of senescence via sustained Ras activation.\",\n      \"evidence\": \"ApoE-/- and stretch models, siRNA and pharmacological inhibition, phosphoproteomics, ATG5/mTOR epistasis, Ras activation assays; P2ry12-/- mice\",\n      \"pmids\": [\"32160082\", \"27534720\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"link between ADP source and chronic receptor activation in vivo incomplete\", \"whether Ras and mTOR arms are connected unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A patient-derived dominant-negative ECL3 variant (R265P) revealed that homodimerization is required for receptor function and links P2Y12 defects to a bleeding phenotype.\",\n      \"evidence\": \"Family sequencing, mutant overexpression, surface expression and Gi signaling assays, dominant-negative co-expression, platelet aggregometry\",\n      \"pmids\": [\"29117459\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"structural basis of dimer interface not directly resolved\", \"single family/lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Microglial knockout work connected P2Y12 to NF-κB/NLRP3 inflammasome-driven cytokine output and to regulation of hippocampal neuronal excitability and innate fear.\",\n      \"evidence\": \"P2Y12-deficient microglia with siRNA and antagonist, NF-κB reporter/cytokine ELISA/caspase-1; constitutive and inducible conditional knockouts with behavior, c-fos and patch clamp\",\n      \"pmids\": [\"31549730\", \"31426845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism coupling P2Y12 to NLRP3 priming versus activation unclear\", \"how microglial signaling alters neuronal excitability not defined molecularly\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Studies defined a PANX1-P2RY12 axis for neurovascular regulation and showed NOD2-driven P2Y12 upregulation underlies platelet hyperactivity in sepsis.\",\n      \"evidence\": \"P2RY12-/- and PANX1-/- mice with two-photon imaging and blood-flow measures; septic patient and CLP platelets, NOD2-/- mice, pAkt/pVASP readouts\",\n      \"pmids\": [\"34489419\", \"34748820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"purine species and source linking PANX1 to P2RY12 not fully resolved\", \"transcriptional control of P2Y12 in platelets versus inheritance unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Convergent studies extended P2Y12 to TGF-β/Smad3-driven macrophage-to-myofibroblast transition in renal fibrosis and to platelet CD40L-dependent anti-tumor CD8+ T cell responses.\",\n      \"evidence\": \"LysM lineage tracing, UUO model, scRNA-seq, siRNA/clopidogrel and Smad3 analysis; P2Y12 depletion with WT versus CD40L-/- platelet transfusion in NAFLD-HCC models\",\n      \"pmids\": [\"35791881\", \"36055226\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"direct receptor-to-Smad3 coupling mechanism not reconstituted\", \"single-lab findings for each context\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Microglial studies linked P2Y12 to Arp2-dependent podosome/filopodia-mediated Tau degradation and to control of general anesthesia depth, broadening its CNS effector and behavioral roles.\",\n      \"evidence\": \"N9 microglia imaging with actin scaffold colocalization and antagonist; microglial conditional knockout, depletion/repopulation and chemogenetics with anesthesia behavioral readouts and scRNA-seq\",\n      \"pmids\": [\"37221563\", \"37167975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"molecular link from P2Y12 to Arp2/podosome machinery not defined\", \"how microglial P2Y12 influences anesthetic targets mechanistically unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single Gαi-coupled receptor is wired to such divergent effector outputs (Ras, mTOR-autophagy, Smad3, NLRP3, RhoA, podosome assembly) in a cell-type-specific manner, and how its active-state G-protein-coupled conformation is structured, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"no active-state ternary (receptor–G protein) structure\", \"cell-type-specific determinants of effector selection unknown\", \"direct biochemical links between receptor and several downstream pathways not reconstituted\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4, 5]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [5, 22]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14, 23, 17]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [\"P2Y12 homodimer\"],\n    \"partners\": [\"NHERF1\", \"GRK2\", \"GRK6\", \"ARRB (arrestin)\", \"PANX1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":9,"faith_total":9,"faith_pct":100.0}}